Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) Income from Continuing Operations: 2023-2025

Historic Income from Continuing Operations for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to -$60.1 million.

  • Immunome's Income from Continuing Operations fell 19.03% to -$60.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$234.2 million, marking a year-over-year increase of 26.23%. This contributed to the annual value of -$305.8 million for FY2024, which is 179.19% down from last year.
  • According to the latest figures from Q3 2025, Immunome's Income from Continuing Operations is -$60.1 million, which was down 29.39% from -$46.5 million recorded in Q2 2025.
  • Over the past 5 years, Immunome's Income from Continuing Operations peaked at -$4.5 million during Q1 2023, and registered a low of -$132.3 million during Q1 2024.
  • Over the past 3 years, Immunome's median Income from Continuing Operations value was -$46.5 million (recorded in 2025), while the average stood at -$51.5 million.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first plummeted by 2,859.05% in 2024, then skyrocketed by 66.26% in 2025.
  • Over the past 3 years, Immunome's Income from Continuing Operations (Quarterly) stood at -$94.7 million in 2023, then grew by 12.34% to -$83.0 million in 2024, then decreased by 19.03% to -$60.1 million in 2025.
  • Its Income from Continuing Operations stands at -$60.1 million for Q3 2025, versus -$46.5 million for Q2 2025 and -$44.6 million for Q1 2025.